You P.,Fudan University |
You P.,Biomedical Imaging Center |
You P.,Shanghai Engineering Research Center for Molecular Imaging Probes |
You P.,Shanghai Normal University |
And 6 more authors.
Current Pharmaceutical Design | Year: 2015
Nano graphene oxide (nGO) is a member of graphene family, which is a novel, one-atom-thickness, two-dimensional carbon nanomaterial. In comparison with graphene, nGO contains much higher extent of reactive chemical functionalities such as hydroxyl, carbonyl, carboxyl, and epoxy group, so as to enable its easier biochemo-functionalization, higher biocompatibility, and greater potentials of applications in biomedicine fields. Up to now, nGO has attracted extensive research interests in nanomedicine and drug delivery systems for cancer imaging and therapy due to its unique biochemical and in vivo properties. This review generally describes the preparation, functionalization, and toxicity of nGO firstly, and then focuses on the studies of biomedical applications for cancer imaging and drug delivery. © 2015 Bentham Science Publishers.
Liu C.,Fudan University |
Liu C.,Shanghai Medical College |
Liu C.,Biomedical Imaging Center |
Liu C.,Shanghai Engineering Research Center for Molecular Imaging Probes |
And 18 more authors.
Nuclear Medicine Communications | Year: 2016
Objective To evaluate the use of fluorine-18 fluorodeoxyglucose (18F-FDG) PET/computed tomography (CT) in the diagnosis of cutaneous extranodal natural killer/ T-cell lymphoma, nasal type (C-ENK/T-NT). Methods A total of 39 patients with newly diagnosed C-ENK/T-NT were enrolled between May 2006 and November 2013. Anatomic regions (n=429; five cutaneous and six extracutaneous regions per patient) were assessed using an 18F-FDG PET/CT scan and conventional staging methods (CSMs). 18F-FDG PET/CT and CSMs were compared and evaluated for their ability to detect tumor lesions and their influence on the staging and treatment strategies. Biopsy and clinical follow-up were used as the gold standard for diagnosis. Results In total, 139 lesions were detected by CSMs and 18F-FDG PET/CT, of which there were 50 cutaneous and 89 extracutaneous-positive regions. 18F-FDG PET/CT detected 48 cutaneous and 88 extracutaneous regions. CSMs, however, detected only 34 cutaneous lesions and 61 extracutaneous lesions that were positive for malignancy (cutaneous comparison of PET/CT vs. CSMs, P<0.001; extracutaneous comparison of PET/CT vs. CSMs, P<0.05). Using 18F-FDG PET/CT, 8 (42%) patients were in stage I II and 31 patients (58%) were in stage III IV. 18F-FDG PET/CT staging was consistent with the final stage determination in 94.9% (37/39) of patients, whereas CSMs staging was correct in final stage determination in 74.4% (29/39) of patients (P=0.025). Conclusion Our study showed that 18F-FDG PET/CT scanning is a valuable modality for the detection of cutaneous and extracutaneous lesions of C-ENK/T-NT. 18F-FDG PET/CT may therefore influence future staging and treatment strategies. © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Wang S.-Y.,Fudan University |
Wang S.-Y.,Biomedical Imaging Center |
Wang S.-Y.,Shanghai Engineering Research Center for Molecular Imaging Probes |
Bao X.,Fudan University |
And 14 more authors.
Applied Radiation and Isotopes | Year: 2015
We estimated the dosimetry of 18F-alfatide II with the method established by MIRD based on biodistribution data of mice. Six mice (three females and three males) were scanned for 160min on an Inveon MicroPET/CT scanner after injection of 18F-alfatide II via tail vein. Eight source organs were delineated on the CT images and their residence times calculated. The data was then converted to human using scaling factors based on organ and body weight. The absorbed doses for human and the resulting effective dose were computed by OLINDA 1.1 software. The highest absorbed doses was observed in urinary bladder wall (male 0.102mGy/MBq, female 0.147mGy/MBq); and the lowest one was detected in brain (male 0.0030mGy/MBq, female 0.0036). The total effective doses were 0.0127mSv/MBq for male and 0.0166 mSv/MBq for female, respectively. A 370-MBq injection of 18F-alfatide II led to an estimated effective dose of 4.70mSv for male and 6.14mSv for female. The potential radiation burden associated with 18F-alfatide II/PET imaging therefore is comparable to other PET examinations. © 2015 Elsevier Ltd.
Sun Y.,Fudan University |
Sun Y.,Biomedical Imaging Center |
Sun Y.,Shanghai Engineering Research Center for Molecular Imaging Probes |
Yang Z.,Fudan University |
And 26 more authors.
PLoS ONE | Year: 2015
January Objective To evaluate the clinical value of 16α-[18F]fluoroestradiol (18F-FES) PET/CT in assisting the individualized treatment decisions of breast cancer patients. Methods Thirty-three breast cancer patients, who underwent both 18F-FES and 18F-FDG PET/CT from July 2010 to March 2013 in our center, were enrolled in this preliminary study. All the patients used 18F-FES PET/CT as a diagnostic tool with a clinical dilemma. We used the maximum Standardized Uptake Value (SUVmax) to quantify ER expression and a cutoff value of 1.5 to dichotomize results into ER positive and negative lesions. All patients were clinically followed up at least 6 months. Results In evaluating equivocal lesions on conventional work-up group (n = 4), three lung lesions and another iliac lesion were enrolled. As for three lung lesions, 18F-FES PET/CT showed one lesion with high uptake, which suggested it was an ER positive metastasis. The other two lesions were 18F-FES negative, which meant an ER negative metastasis or secondary primary tumor. Additionally, one iliac lesion was detected by MRI. 18F-FDG uptake was high at the suspected lesion, whereas 18F-FES uptake was absent; In predicting origin of metastasis group (n = 2), two breast cancer patients had secondary primary tumors were collected. They were 18F-FES negative, which showed low possibility of metastasis from breast cancer and they were all confirmed by biopsy. In detecting ER status in metastasis group (n = 27), 18F-FES PET/CT showed increased 18F-FES uptake in all metastatic lesions in 11 patients; absent in all lesions in 13 patients; and the remaining 3 patients had both 18F-FES positive and negative lesions. Totally, on the basis of the 18F-FES PET/CT results, we found changes in the treatment plans in 16 patients (48.5%, 16/33). Conclusions 18F-FES PET/CT could assess the entire tumor volume receptor status; therefore, it may be used to assist the individualized treatment decisions of breast cancer patients. © 2015 Sun et al.